Latest Headlines

Latest Headlines

Bacterial cancer vaccines show glimpses of activity

Therapeutic vaccines could prove to be a good way to tackle cancer. A few shots and--it is hoped--only a few side effects, rather than long treatments with traditional chemotherapy drugs that make...

Gold out, Johnson in as troubled Dendreon aims for a turnaround

In the course of one short year, Dendreon CEO Mitch Gold went from biotech hero to zero as the long-anticipated rollout of the groundbreaking cancer vaccine Provenge stumbled badly out of the gate.

Cancer immunotherapy partners face big test with Phase III program

Merck KGaA and Oncothyreon ($ONTY) will learn soon whether their lung cancer vaccine has a shot at being one of the next bright lights in the cancer immunotherapy arena, with an interim analysis set

Dendreon demonstrates tougher commercialization hurdles for developers

It takes years in biotechnology to forge an enduring success. But failure is always just one false step away. Look at Dendreon ($DNDN). A little more than a year ago, the biotech pioneer was

Dendreon's Gold tops 'Worst Biotech CEO' poll

Mitch Gold and his struggling biotech Dendreon ($DNDN) can't catch a break since disappointing Wall Street with lackluster sales of the prostate cancer drug Provenge. TheStreet announced Gold was

Celldex shares rally (briefly) on positive PhII brain cancer data

Celldex Therapeutics ($CLDX) reports that a small, single-arm study of its experimental brain cancer vaccine scored a significantly higher overall survival rate than the historical numbers on file.

Nobel winner fought his cancer with own research until death

Dr. Ralph Steinman became the subject of his own pioneering research in the field of immunology after he was diagnosed with pancreatic cancer four and half years ago. After winning a Nobel prize this

Dendreon cuts deep into work force to conserve cash

In an attempt to break even in the cash-intensive biotech game following a rough start with its prostate cancer drug, Dendreon is handing pink slips to a quarter of its employees and saying goodbye

Dendreon banks on restructuring after stock craters

Struggling to break out of Wall Street's dog house, Dendreon is pursuing a corporate restructuring plan that many expect to result in big cost cuts and the potential elimination of jobs at the

Dendreon cancels GSK Provenge contract

After months of poor sales, Dendreon ($DNDN) terminated its Provenge contract with GlaxoSmithKline ($GSK). The pharma giant would have provided the cancer vaccine's antigen through 2015 as part of